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Abstract
Background—The eVect of hepatitis delta
virus (HDV) infection on the clinical
course of cirrhosis type B is poorly
defined.
Aims—To investigate the impact of HDV
status on morbidity and mortality in
cirrhosis type B.
Patients/Methods—Retrospective cohort
study of 200 Western European patients
with compensated cirrhosis type B fol-
lowed for a median period of 6.6 years.
Results—At diagnosis, 20% of patients had
antibodies to HDV (anti-HDV); median
age was lower in anti-HDV positive cir-
rhotics (34 v 48 years respectively).
Kaplan-Meier five year probability of
hepatocellular carcinoma (HCC) was 6,
10, and 9% in anti-HDV positive/HBeAg
negative, anti-HDV negative/HBeAg
negative, and anti-HDV negative/HBeAg
positive cirrhotics respectively; the corre-
sponding figures for decompensation were
22, 16, and 19% and for survival they were
92, 89, and 83% respectively. Cox
regression analysis identified age, albu-
min concentration, ã-globulin concentra-
tion, and HDV status as significant
independent prognostic variables. After
adjustment for clinical and serological
diVerences at baseline, the risk (95% con-
fidence interval) for HCC, decompensa-
tion, and mortality was increased by a
factor of 3.2 (1.0 to 10), 2.2 (0.8 to 5.7), and
2.0 (0.7 to 5.7) respectively in anti-HDV
positive relative to HDV negative cirrhotic
patients. The adjusted estimated five year
risk for HCC was 13, 4, and 2% for
anti-HDV positive/HBeAg negative, anti-
HDV negative/HBeAg negative, and anti-
HDV negative/HBeAg positive cirrhotics
respectively; the corresponding figures for
decompensation were 18, 8, and 14% and
for survival 90, 95, and 93% respectively.
Conclusions—HDV infection increases
the risk for HCC threefold and for
mortality twofold in patients with cirrho-
sis type B.
(Gut 2000;46:420–426)
Keywords: delta hepatitis; prognosis; hepatocellular
carcinoma; decompensation; survival
The hepatitis delta virus (HDV) is a defective
pathogen which requires for infection the
helper functions of hepatitis B virus (HBV).1 It
is responsible for acute or chronic hepatitis.
Acute delta hepatitis may occur either by
simultaneous co-infection with HDV and HBV
or by HDV superinfection in a person already
chronically infected with HBV. Chronicity of
HDV infection most commonly develops after
acute delta superinfection.2
Numerous clinical studies have reported that
patients with chronic HDV infection often
show severe chronic hepatitis or cirrhosis on
initial liver biopsy.3–5 Cross sectional studies
have indicated that patients with hepatitis B
surface antigen (HBsAg) positive chronic
hepatitis and HDV infection have more severe
liver disease than those with HBV infection
alone.6 Moreover longitudinal studies have
reported that HDV infection in patients with
chronic hepatitis B is associated with a more
rapid progression to cirrhosis than in HBsAg
carriers with chronic hepatitis and no evidence
of HDV infection.7 Overall, these data indicate
that HDV infection tends to influence unfa-
vourably the clinical outcome of chronic hepa-
titis B. However at present, there are insuY-
cient data to clarify whether HDV alters the
clinical course of HBV related compensated
cirrhosis and increases the risk of hepatocellu-
lar carcinoma (HCC). The aim of this study
was to investigate the impact of HDV infection
on the prognosis of compensated cirrhosis type
B in a cohort of 200 Western European
patients followed untreated for a median
period of 6.6 years. Morbidity, namely inci-
dence of complications of cirrhosis and inci-
dence of HCC, and mortality were compared
in anti-HDV positive and negative patients.
Materials and methods
PATIENTS
The study is based on analysis of data derived
from a longitudinal study of compensated
cirrhosis due to HBV, which involved nine ter-
tiary referral university hospitals in Europe
participating in the Concerted Action on Viral
Hepatitis named Eurohep. The details of the
overall design of this study have been described
previously.8 Briefly, all patients meeting the fol-
lowing criteria were evaluated in the present
investigation: (a) HBsAg positivity; (b) histo-
logical diagnosis of cirrhosis according to
international criteria9; (c) no history or clinical
Abbreviations used in this paper: HDV, hepatitis
delta virus; HBV, hepatitis B virus; HBsAg, hepatitis B
surface antigen; HBeAg, hepatitis B e antigen; ELISA,
enzyme linked immunosorbent assay; HCC,
hepatocellular carcinoma.
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evidence of complications of cirrhosis—that is,
ascites, variceal bleeding, encephalopathy, or
jaundice; (d) no evidence of HCC at diagnosis;
(e) information on serum hepatitis B e antigen
(HBeAg) and antibody to HDV (anti-HDV) at
presentation; (f) follow up at the enrolling cen-
tre for a minimum period of six months; (g) no
antiviral or steroid treatment during follow up.
These entry criteria resulted in a cohort of
Child-Pugh class A patients. Patients with
autoimmune or metabolic liver disease were
excluded by history, serological variables, and
histology.
The starting time for morbidity and survival
analysis was the time of diagnosis of HBsAg
positive compensated cirrhosis. The follow up
was calculated from the date of entry until
death, liver transplantation, or the last observa-
tion. All patients were evaluated at least once a
year or at more frequent intervals as indicated
by their clinical conditions. Death was classi-
fied as being caused by liver failure if (a)
progressive impairment of liver function oc-
curred or (b) it occurred within 40 days of
variceal bleeding, regardless of the severity, or
as being caused by HCC. The diagnosis of
HCC was based on either liver biopsy or á
fetoprotein levels of more than 400 µg/l plus
compatible liver ultrasonography. Decompen-
sation was defined as at least one episode of
ascites, jaundice, hepatic encephalopathy, or
gastrointestinal bleeding of variceal origin.
SEROLOGICAL TESTING
Virological data were obtained by review of the
patients’ charts or were retrospectively ob-
tained using stored serum samples. HDV
infection was diagnosed on the basis of
anti-HDV in the serum and hepatitis delta
antigen in the liver. HBsAg, HBeAg, antibody
to HBeAg (anti-HBe), anti-HDV, and antibody
to HIV (anti-HIV) were tested for by commer-
cially available radioimmunoassays or enzyme
linked immunosorbent assays (ELISAs).
Serum HBV DNA was measured by a spot
hybridisation or by a solution hybridisation
assay. Serum antibody to hepatitis C virus was
tested for by a second generation ELISA.
Hepatitis delta antigen in the liver was tested
for by direct immunofluorescence using fluo-
rescein isothiocyanate conjugated anti-HDV
serum on frozen unfixed liver sections or by
immunoperoxidase staining using commer-
cially available polyclonal anti-HDV on paraf-
fin wax embedded material.
STATISTICAL ANALYSIS
Statistical analyses were performed by the ÷2
test and the analysis of variance test to
compare diVerences between proportions and
medians respectively. The cumulative prob-
ability of HCC appearance, decompensation
occurrence, and survival were calculated by
the Kaplan-Meier method.10 Because a minor-
ity of cirrhotics were anti-HDV/HBeAg posi-
tive, this analysis is based on data condensed
into three groups of cirrhotics: anti-HDV
positive/HBeAg negative, anti-HDV negative/
HBeAg negative, and anti-HDV negative/
HBeAg positive. Patients who died from
conditions not related to liver disease, those
undergoing liver transplantation, and patients
who were lost to follow up were censored at
the time of death, at the time of transplanta-
tion, or at the time of drop out in this
analysis.10 Curves were compared using the log
rank test.11 Prognostic factors for HCC,
decompensation, and survival were identified
using Cox regression analysis,12 13 both uni-
variate and multivariate, with backward elimi-
nation of insignificant variables. Potential
prognostic factors assessed for morbidity and
mortality included the following clinical,
biochemical, and virological variables
measured at enrolment: sex, age, log10 (bi-
lirubin concentration), levels of albumin,
ã-globulins, and platelets, HBeAg and anti-
HDV status. Sex (male = 1, female = 0), anti-
HDV (positive = 1, negative = 0), and HBeAg
(positive =1, negative =0) were introduced as
dichotomous variables. To analyse the influ-
ence of HDV status on clinical end points, the
Cox model included at all stages, whether sig-
nificant or not, the indicator term of HDV sta-
tus (anti-HDV positive = 1, negative = 0), and
in the model obtained the p value for the HDV
term shows directly the significance of the
HDV status adjusted for the influence of all
the other prognostic variables included. Be-
cause the analysis requires that all patients are
represented by a complete set of variables and,
in order not to reduce the number of patients,
missing data were replaced by neutral
estimates.14 The adjusted relative risks (HDV
positive/HDV negative) (with 95% confidence
limits) for HCC, decompensation, and sur-
vival were estimated from the regression coef-
ficient (and SE) for the HDV status in models
including variables, the influence of which was
to be adjusted for.14 The adjusted curves for
the probability of HCC or decompensation
occurrence and for survival were estimated
from the regression models as previously
described.14 The statistical software used was
BMDP. In all analyses, a p value less than 0.05
was considered statistically significant.
Results
BASELINE CHARACTERISTICS ACCORDING TO
ANTI-HDV/HBeAG STATUS
We evaluated 200 white patients with HBsAg
positive compensated cirrhosis who fulfilled
the inclusion criteria. This series represents all
untreated white patients enrolled in a previous
study8 evaluating survival of compensated
cirrhosis type B, except 17 of oriental or black
origin, 36 with antibody to hepatitis C virus
and/or anti-HIV positivity, and 113 who had
received antiviral (n = 87) or steroid (n = 26)
treatment.
At enrolment, 39 (20%) patients were
anti-HDV positive, including two HBeAg posi-
tive cases, and 161 patients were anti-HDV
negative, including 45 HBeAg positive cirrhot-
ics.
Table 1 gives a comparison of the main clini-
cal and serological patient features according
to HDV and HBeAg status at presentation.
Median age was lower in the anti-HDV positive
patients, while no significant diVerence was
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noted in the gender. Assessment of the
probable source of infection showed a higher
proportion of household contacts and drug
addicts among patients with HDV related
cirrhosis. Anti-HDV positive patients had
higher ã-globulin concentrations and slightly
lower platelet levels. When just tested, a smaller
proportion of anti-HDV positive/HBeAg nega-
tive cirrhotics had evidence of HBV DNA
detectable in the serum than did anti-HDV
negative/HBeAg negative patients (7% v 30%
respectively).
CLINICAL OUTCOME ACCORDING TO
ANTI-HDV/HBeAG STATUS
The 200 patients were followed for a median
period of 80 (range 6–198) months. The dura-
tion of follow up was comparable for the anti-
HDV positive and negative patients (p = 0.2),
and so were the drop out rates (p = 0.2) (table
2).
Development of HCC
As shown in table 2, during follow up, HCC
developed in five (13%) anti-HDV positive/
HBeAg negative, 19 (16%) anti-HDV negative/
HBeAg negative, and three (7%) anti-HDV
negative/HBeAg positive patients with cirrhosis
type B; the median age of patients at the time of
diagnosis of HCC was 54 (range 51–63), 62
(range 40–76), and 64 (52–78) years for the
three groups of cirrhotics respectively. The
median interval between the time of entry into
the study and the diagnosis of HCC was 75
(range 17–128) months for anti-HDV positive/
HBeAg negative patients, 48 (range 7–181)
months for anti-HDV negative/HBeAg nega-
tive patients, and 40 (range 7–44) months for
anti-HDV negative/HBeAg positive cirrhotics.
The unadjusted five year cumulative incidence
of HCC was 6, 10, and 9% for anti-HDV
positive/HBeAg negative, anti-HDV negative/
HBeAg negative, and anti-HDV negative/
HBeAg positive cirrhotics respectively (fig 1,
top).
Factors correlating with HCC
Among the clinical and biochemical features
studied by univariate analysis, older age, lower
platelet levels, and higher bilirubin concentra-
tion were significantly associated with a higher
risk of HCC (table 3).
In multiple Cox regression analysis, an older
age (p<0.0001) and anti-HDV positivity (p =
0.05) were independently and significantly
associated with a higher risk of HCC (table 4).
As shown in table 5, HDV superinfection
significantly increased the risk for HCC by a
factor of 3.2 (fully adjusted relative risk).
The estimated fully adjusted five year risk of
HCC occurrence (using median values of the
variables at baseline in the Cox model) was 13,
4, and 2% for anti-HDV positive/HBeAg nega-
tive, anti-HDV negative/HBeAg negative, and
anti-HDV negative/HBeAg positive cirrhotics
respectively (fig 1, bottom).
Table 1 Baseline features of 200 patients with cirrhosis type B (Child A) according to hepatitis delta virus (HDV) and
hepatitis B e antigen (HBeAg) status
Anti-HDV+/
HBeAg− (n = 37)
Anti-HDV+/
HBeAg+ (n = 2)
Anti-HDV−/
HBeAg− (n = 116)
Anti-HDV−/
HBeAg+ (n = 45) p Value
Patient characteristics
Male (%) 76 100 90 87 NS
Age (years) 34 (13–62) 25 (23–28) 49 (23–75) 47 (11–78) 0.0001
Source of infection
Household contact 4 (11) 1 (50) 1 (1) 1 (2) 0.004
Vertical transmission 1 (3) 0 3 (3) 2 (4)
Sexual transmission 0 0 5 (4) 6 (13)
Medical exposure 2 (5) 0 2 (2) 3 (7)
Blood transfusion 1 (3) 0 2 (2) 3 (7)
Drug addiction 2 (5) 1 (50) 1 (1) 0
Unknown 27 (73) 0 102 (87) 30 (67)
Biochemistry
AST:ALT ratio 0.8 (0.19–1.54) 0.65 (0.48–0.82) 0.86 (0.19–2.94) 0.72 (0.09–2.14) NS
Bilirubin (µmol/l) 15 (5.9–35.7) 14.2 (13–15.4) 14 (5–51) 13.6 (2.3–38.5) NS
Albumin (g/l) 41 (29–48) 45.5 (43–48) 40 (25–52.4) 41 (27.3–53.3) NS
ã-globulin (g/l) 21 (9–46) 19 (12–26) 16 (7–39.7) 16.8 (7.9–38) 0.012
Platelets (109/l) 131 (38–276) 238 (216–261) 150 (31–340) 160 (68–287) NS
For statistical analysis, three groups were considered: anti-HDV+/HBeAg−, anti-HDV−/HBeAg−, and anti-HDV−/HBeAg+.
p Value derived from analysis of variance or ÷2 test.
Data are expressed as median (range) or as number of patients (%).
anti-HDV, antibody to HDV; NS, non significant; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Table 2 Clinical outcome of 200 patients with cirrhosis type B (Child A) according to hepatitis delta virus (HDV) and
hepatitis B e antigen (HBeAg) status
Anti-HDV+/
HBeAg− (n = 37)
Anti-HDV+/HBeAg+
(n = 2)
Anti-HDV−/HBeAg−
(n = 116)
Anti-HDV−/
HBeAg+ (n = 45)
HCC 5 (13) 0 19 (16) 3 (7)
Decompensation* 12 (37) 0 20 (21) 11 (26)
Liver related death 6 (16) 0 23 (20) 9 (20)
Cause of death
HCC 3 - 12 2
Liver failure 3 - 11 7
Unrelated 0 - 3 2
Lost to follow up 3 (8) 0 6 (5) 2 (4)
Median (range) follow up (months) 90 (14–198) 83 (57–109) 79 (6–181) 66 (4–191)
Values are expressed as number of patients (%). *Values were calculated for 173 patients who remained tumour free.
HCC, hepatocellular carcinoma.
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Development of decompensation
Of the 173 patients who remained tumour free,
12 (37%) anti-HDV positive/HBeAg negative,
20 (21%) anti-HDV negative/HBeAg negative,
and 11 (26%) anti-HDV negative/HBeAg
positive cirrhotics developed at least one
episode of decompensation (table 2). The
unadjusted five year probability of decompen-
sation was 22, 16, and 19% in the three
subgroups of cirrhotics respectively (fig 2, top).
Factors correlating with decompensation
By univariate analysis the following variables
were significantly associated with a higher risk
of decompensation: older age, lower albumin
concentration, higher ã-globulin concentra-
tion, and lower platelet levels (table 3).
In multivariate analysis, lower albumin con-
centration (p = 0.0001) and higher ã-globulin
concentration (p<0.0001) independently
showed significant association with a higher
risk of decompensation (table 4).
HDV superinfection increased the risk for
decompensation, although not significantly, by
a factor of 2.2 (fully adjusted relative risk)
(table 5).
The estimated fully adjusted five year
probability of decompensation (using median
values of the variables at baseline in the Cox
model) was 18, 8, and 14% for anti-HDV
positive/HBeAg negative, anti-HDV negative/
HBeAg negative, and anti-HDV negative/
HBeAg positive patients respectively (fig 2,
bottom).
Survival
During follow up, liver related death occurred
in six (16%) anti-HDV positive/HBeAg nega-
tive patients, 23 (20%) anti-HDV negative/
HBeAg negative, and nine (20%) anti-HDV
negative/HBeAg positive cirrhotics (table 2).
Decompensated cirrhosis necessitating liver
transplantation occurred in four, two, and two
other patients in the three subgroups of
cirrhotics respectively. The unadjusted five year
probability of survival was 92, 89, and 83 in
anti-HDV positive/HBeAg negative, anti-
HDV-negative/HBeAg negative, and anti-HDV
negative/HBeAg positive cirrhotics respectively
(fig 3, top).
Factors correlating with survival
By univariate analysis, older age, lower albumin
concentration, and higher ã-globulin concen-
tration were significantly associated with a
decreased survival (table 3).
In multivariate analysis, older age
(p<0.0001), lower albumin concentration (p =
0.0027), and higher ã-globulin concentration
(p = 0.026) independently showed association
with a decreased survival (table 4).
As shown in table 5, HDV superinfection
increased mortality, although not significantly,
by a factor of 2 (fully adjusted relative risk).
The estimated fully adjusted five year
survival (using median values of the variables at
baseline in the Cox model) was 90, 95, and
93% for anti-HDV positive/HBeAg negative,
anti-HDV negative/HBeAg negative, and anti-
Figure 1 Cumulative probability of hepatocellular carcinoma (HCC) appearance in
patients with compensated cirrhosis type B (Child A) in relation to anti-hepatitis delta
virus (HDV) and hepatitis B e antigen (HBeAg) status. The five year appearance rate
was 6, 10, and 9% for anti-HDV positive/HBeAg negative (thick line), anti-HDV
negative/HBeAg negative (thin line), and anti-HDV negative/HBeAg positive (dashed
line) patients respectively (p = 0.33, log rank test) (top). The estimated five year
probability adjusted for all potential prognostic variables by Cox model was 13, 4, and 2%
for anti-HDV positive/HBeAg negative, anti-HDV negative/HBeAg negative, and
anti-HDV negative/HBeAg positive patients respectively (bottom).
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Table 3 Univariate Cox analysis for hepatocellular carcinoma (HCC) occurrence,
decompensation appearance, and survival in 200 patients with cirrhosis type B (Child A)
Outcome Variable
â regression
coeYcient SE p Value
HCC Age 0.0905 0.0182 0.00001
Platelets −0.0090 0.0039 0.0194
Bilirubin 1.8998 0.8700 0.0290
Albumin −0.0506 0.0401 0.2074
ã-globulins 0.0152 0.0296 0.6070
Sex −0.0498 0.5452 0.9273
HDV status −0.2708 0.4965 0.5855
HBeAg status −0.7818 0.6136 0.2026
Decompensation Age 0.0250 0.0123 0.0429
Albumin −0.1409 0.0297 0.00001
ã-globulins 0.1138 0.0189 0.00001
Platelets −0.0119 0.0029 0.00001
Bilirubin 1.0291 0.7346 0.1612
Sex −0.6765 0.3614 0.0612
HDV status 0.3217 0.3404 0.3447
HBeAg status 0.1052 0.3499 0.7638
Survival Age 0.0720 0.0148 0.00001
Albumin −0.1170 0.0309 0.0002
ã-globulins 0.0684 0.0202 0.0007
Platelets −0.0052 0.0031 0.1001
Bilirubin 1.0810 0.7166 0.1314
Sex −0.3391 0.4195 0.4190
HDV status −0.4459 0.4455 0.3168
HBeAg status 0.1809 0.3823 0.6361
Table 4 Cox regression models including only significant
variables (and HDV status) for prediction of hepatocellular
carcinoma (HCC) occurrence, decompensation appearance,
and survival
Outcome Variable
â regression
coeYcient SE p Value
HCC Age 0.1044 0.0199 0.00001
HDV status 1.0908 0.5622 0.0523
Decompensation Albumin −0.1334 0.0332 0.0001
ã-globulins 0.1020 0.0201 0.00001
HDV status 0.3171 0.3572 NS
Survival Age 0.0769 0.0171 0.00001
Albumin −0.1032 0.0344 0.0027
ã-globulins 0.0499 0.0225 0.0269
HDV status 0.3596 0.4991 NS
p Value derived from Wald test.
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HDV negative/HBeAg positive cirrhotics re-
spectively (fig 3, bottom).
Discussion
The main findings of our study concern the
clinical expression of HDV infection in West-
ern European patients with compensated
cirrhosis (Child A) on their first presentation at
tertiary referral centres and the impact of HDV
infection on morbidity and mortality in cirrho-
sis type B.
The 20% prevalence of anti-HDV in 200
HBsAg positive cirrhotics closely parallels the
data from previous European studies of
chronic HBsAg carriers.15 16 Our results indi-
cate that HDV infection modifies to a certain
extent the clinical and serological presentation
of HBsAg positive cirrhosis. In fact the
presence of anti-HDV in serum identified a
subgroup of cirrhotic patients who were
younger and had higher serum levels of
ã-globulins and slightly lower platelet levels
compared with anti-HDV negative cirrhotics.
In addition, characteristic features of these
anti-HDV positive patients were the high
prevalence of anti-HBe in serum and the low
rate of active HBV replication, as indicated by
the detection of serum HBeAg and/or HBV
DNA in a small proportion of about 10% of the
patients tested. These results are consistent
with the fact that HDV suppresses the synthe-
sis of HBV genome and serum HBV DNA
often remains undetectable by traditional
methods both at the acute and chronic stage of
HDV superinfection.17 18 It is interesting to
note that these findings are in agreement with
previous observations obtained in prospective
studies of patients with HBsAg positive chronic
hepatitis that HDV infection aVects mainly
young anti-HBe positive patients and is associ-
ated with a more rapid progression to
cirrhosis.7 19 It has been reported that, in about
15% of cases of chronic delta hepatitis, the dis-
ease is rapidly progressive, with cirrhosis devel-
oping within two years of onset,19 and our data
indicate that patients with superimposed delta
infection may progress to cirrhosis about 15
years earlier than those with HBV infection
(median age at diagnosis of cirrhosis 34 v 48
years in anti-HDV positive and negative
patients respectively).
The analysis of potential risk factors for
HDV infection in our study population con-
firms that parenteral drug addicts are at highest
risk and play a major role in the spread of the
delta agent in the western world. HDV
infection was also related to household contact
with an HBsAg positive carrier, which is in
agreement with previous observations that
intrafamily contact may favour the spread of
infection, particularly in areas of southern
Europe where the delta agent is endemic.15 16
Few data are available on the clinical course
of compensated cirrhosis associated with delta
infection. Previous longitudinal studies on the
outcome of delta cirrhosis have only included a
small number of cirrhotic patients and/or have
not distinguished between compensated and
decompensated cirrhosis.3 20 In addition, at
present the question is whether HDV alters the
clinical course of HBV related compensated
cirrhosis and increases the risk of HCC.
The impact of HDV infection on the clinical
course of compensated cirrhosis type B (Child
A) has been analysed in our cohort of 200
untreated patients followed for a median
period of 6.6 years; morbidity and mortality
were evaluated in delta positive/HBeAg nega-
tive cirrhotics and compared with two groups
of delta negative patients, namely 116 HBeAg
negative and 45 HBeAg positive. The unad-
justed Kaplan-Meier analysis of the cumulative
Table 5 EVect of hepatitis delta virus (HDV) status on hepatocellular carcinoma (HCC) occurrence, decompensation
appearance, and survival
HCC Decompensation Survival
â regression
coeYcient (SE) RR (95% CI)
â regression
coeYcient (SE) RR (95% CI)
â regression
coeYcient (SE) RR (95% CI)
Univariate analysis −0.2708 (0.4965) 0.8 (0.3 to 2.0) 0.3217 (0.3404) 1.4 (0.7 to 2.7) −0.4459 (0.4455) 0.6 (0.3 to 1.5)
Multivariate analysis
A 1.0908 (0.5622) 3.0 (1.0 to 9.0) 0.3171 (0.3572) 1.4 (0.7 to 2.8) 0.3596 (04991) 1.4 (0.5 to 3.8)
B 1.1525 (0.5846) 3.2 (1.0 to 10.0) 0.7810 (0.4916) 2.2 (0.8 to 5.7) 0.6702 (05466) 2.0 (0.7 to 5.7)
A. Relative risk (RR) estimates (95% confidence interval (CI)) adjusted for significant prognostic variables by Cox model (see table 4).
B. RR estimates (95% CI) adjusted for all potential prognostic variables by Cox model (age, sex, log10 (bilirubin), albumin,
ã-globulins, platelets, HBeAg status).
Figure 2 Cumulative probability of developing decompensation in patients with
compensated cirrhosis type B (Child A) in relation to anti-hepatitis delta virus (HDV) and
hepatitis B e antigen (HBeAg) status. The analysis included 171 patients who remained
tumour free. The five year probability of decompensation was 22, 16, and 19% for
anti-HDV positive/HBeAg negative (thick line), anti-HDV negative/HBeAg negative
(thin line), and anti-HDV negative/HBeAg positive (dashed line) patients (p = 0.38, log
rank test) (top). The estimated five year probability adjusted for all potential prognostic
variables by Cox model was 18, 8, and 14% for anti-HDV positive/HBeAg negative,
anti-HDV negative/HBeAg negative, and anti-HDV negative/HBeAg positive patients
respectively (bottom).
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incidence of HCC and decompensation and of
survival probability showed no significant dif-
ference between the three subgroups of
patients (figs 1, 2, and 3 top). In addition, by
univariate prognostic Cox analysis, HDV
status is not a significant predictor of clinical
outcome and has a negative B regression coef-
ficient for HCC and survival (table 5)—that is,
it tends to be associated with a lower risk for
liver tumour and a longer survival—but these
data are partly explained by the younger age of
the anti-HDV positive patients. As age is a very
powerful prognostic variable for HCC and
survival (table 4), its inclusion has a pro-
nounced eVect in the multivariate analysis,
where HDV status has a positive B regression
coeYcient—that is, higher risk for HCC
occurrence and worse survival if anti-HDV is
positive—and becomes significant for liver
tumour occurrence (table 5). These data indi-
cate that univariate analysis can be misleading
and that the HDV eVect needs to be adjusted
in a multivariate analysis. In addition to age,
albumin and ã-globulin levels were found to be
independent predictors of clinical outcome in
the multivariate analysis. In the current study,
albumin is a strong prognostic variable for
decompensation and survival. Only a minority
(17%) of our patients with Child A cirrhosis
had serum levels of albumin lower than 35 g/l,
further indicating that albumin is a sensitive
marker of hepatic insuYciency in cirrhosis.
Hypergammaglobulinaemia in cirrhosis is
considered to be a consequence of chronic
exposure to exogenous antigen absorbed
mainly from the gut as the result of an
impaired hepatic reticuloendothelial systemic
phagocytic activity related to intrahepatic
shunting of blood.21 22 In addition, recent data
indicate that high levels of endotoxin antibod-
ies contribute to hypergammaglobulinaemia in
cirrhotic patients, probably as a result of
chronic endotoxin exposure.23 Therefore
serum ã-globulin levels have a prognostic
value because they reflect the degree of altera-
tion of the hepatic circulation in the cirrhotic
liver.
The prognosis in cirrhosis varies widely
according to patient characteristics. As shown
in table 5, it appears that for all the three end
points evaluated (HCC, decompensation, and
survival) the adjusted HDV eVect tends to be
harmful (positive B regression coeYcient) and
that the estimated risk for HCC or decompen-
sation occurrence and for shorter survival
increases by a factor of 2 or more, although this
is only significant for HCC. Accordingly, after
adjustment for clinical and serological diVer-
ences at baseline, the estimated five year prob-
ability of HCC, decompensation occurrence
was highest and of survival was lowest in anti-
HDV positive patients (figs 1, 2, and 3,
bottom).
The probability of survival (about 90% at
five years) observed in our delta cirrhotics was
higher than that (71%) previously reported at
five years in a Dutch study.20 This finding may
be explained by diVerences in patient charac-
teristics at entry, as the study from The Neth-
erlands also included patients at an advanced
stage of cirrhosis (Child B and C). In our study
we have analysed only patients with biopsy
proven compensated cirrhosis, but no data are
available about how many potential cirrhotics
were excluded because they did not have a liver
biopsy or because they already had clinical evi-
dence of advanced cirrhosis, and it is possible
that there may have been a selection bias to
exclude delta positive or delta negative patients
with more severe liver disease
In conclusion, the most important character-
istic of chronic delta hepatitis appears to be its
propensity to progress rapidly to cirrhosis, and
our longitudinal study conducted in patients
with compensated cirrhosis type B indicates
that concomitant HDV infection is associated
with a threefold increased risk for HCC and
with a twofold increased risk of mortality, con-
firming the poor prognosis in this subgroup of
patients.
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